文献速递消化系统肿瘤支持与姑息治疗

韩国红参改善结直肠癌化疗患者癌因性疲乏:随机III期试验

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial.
PubMed 文献 · Eur J Cancer · 2020-03-13

这项随机双盲III期试验纳入接受mFOLFOX-6化疗的结直肠癌患者,随机分配至韩国红参2000 mg/日组(n=219)或安慰剂组(n=219)共16周。主要终点为简明疲乏量表(BFI)从基线的平均AUC变化。结果显示韩国红参可改善癌因性疲乏,尤其在情绪和行走能力方面,且总体不良事件发生率与安慰剂相似。

要点

  • 韩国红参2000 mg/日联合mFOLFOX-6化疗可改善结直肠癌患者癌因性疲乏。
  • 全分析集显示情绪和行走能力改善显著(P=0.038和P=0.023)。
  • 女性、≥60岁、高依从性或基线疲乏较重者获益更明显。

核心结论

  • 韩国红参可安全联合mFOLFOX-6化疗,并较安慰剂改善结直肠癌患者的癌因性疲乏。

研究设计与样本

  • 随机双盲III期试验,纳入接受mFOLFOX-6化疗的结直肠癌患者,随机分配至韩国红参2000 mg/日组(n=219)或安慰剂组(n=219),干预16周。

主要发现

  • 全分析集中,韩国红参组BFI从基线的平均AUC变化优于安慰剂,情绪和行走能力改善显著(P=0.038和P=0.023)。
  • 符合方案集中,韩国红参组全局BFI评分较安慰剂改善(P=0.019)。
  • 第16周时,韩国红参组在「此刻疲乏」「情绪」「与他人的关系」「行走能力」「生活乐趣」方面均有改善(P=0.045、P=0.006、P=0.028、P=0.003、P=0.036)。
  • 女性、≥60岁、依从性高(≥80%)或基线疲乏较重的亚组中,韩国红参的获益较安慰剂更明显。
  • 中性粒细胞减少在韩国红参组较安慰剂组更常见,但所有不良事件的发生率相似。

临床怎么用

  • 对于接受mFOLFOX-6化疗的结直肠癌患者,可考虑联合韩国红参2000 mg/日以改善癌因性疲乏,但需注意中性粒细胞减少的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer-related fatigue (CRF) is a common symptom and has a negative impact on prognosis in cancer patients. CRF could be improved by Korean red ginseng (KRG). PATIENTS AND METHODS: For this randomised and double-blinded trial, colorectal cancer patients who received mFOLFOX-6 were randomly assigned to either KRG 2000 mg/day (n = 219) or placebo (n = 219) for 16 weeks. CRF was evaluated using the mean area under the curve (AUC) change from baseline of brief fatigue inventory (BFI) as the primary endpoint. Fatigue-related quality of life, stress, and adverse events were evaluated as secondary endpoints. RESULTS: In the full analysis group, KRG up to 16 weeks improved CRF by the mean AUC change from baseline of BFI compared to placebo, particularly in "Mood" and "Walking ability" (P = 0.038, P = 0.023, respectively). In the per-protocol group, KRG led to improved CRF in the global BFI score compared with the placebo (P = 0.019). Specifically, there were improvements in "Fatigue right now," "Mood," "Relations with others," "Walking ability," and "Enjoyment of life" at 16 weeks (P = 0.045, P = 0.006, P = 0.028, P = 0.003, P = 0.036, respectively). In subgroups of female patients, ≥60 years old, with high compliance (≥80%) or more baseline fatigue, the beneficial effects of KRG were more enhanced than that of placebo. Although neutropenia was more frequent in KRG than placebo, the incidence of all adverse events was similar. CONCLUSIONS: KRG could be safely combined with mFOLFOX-6 chemotherapy in colorectal cancer patients, and reduced CRF compared with placebo.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim JW, Han SW, Cho JY, et al. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. Eur J Cancer. 2020. PMID: 32172198. doi:10.1016/j.ejca.2020.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。